Cargando…
Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer
BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have d...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087601/ https://www.ncbi.nlm.nih.gov/pubmed/33754186 http://dx.doi.org/10.1007/s00404-021-06028-4 |
_version_ | 1783686698148823040 |
---|---|
author | Raffone, Antonio Travaglino, Antonio Gabrielli, Olimpia Micheli, Mariacarolina Zuccalà, Valeria Bitonti, Giovanna Camastra, Caterina Gargiulo, Valentina Insabato, Luigi Zullo, Fulvio |
author_facet | Raffone, Antonio Travaglino, Antonio Gabrielli, Olimpia Micheli, Mariacarolina Zuccalà, Valeria Bitonti, Giovanna Camastra, Caterina Gargiulo, Valentina Insabato, Luigi Zullo, Fulvio |
author_sort | Raffone, Antonio |
collection | PubMed |
description | BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking. OBJECTIVE: To provide a clinical characterization of the ProMisE groups of EC. METHODS: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated. RESULTS: Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%. CONCLUSION: The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-021-06028-4. |
format | Online Article Text |
id | pubmed-8087601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-80876012021-05-05 Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer Raffone, Antonio Travaglino, Antonio Gabrielli, Olimpia Micheli, Mariacarolina Zuccalà, Valeria Bitonti, Giovanna Camastra, Caterina Gargiulo, Valentina Insabato, Luigi Zullo, Fulvio Arch Gynecol Obstet Review BACKGROUND: The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) groups has identified four molecular prognostic groups of endometrial cancer (EC): POLE-mutated (POLE-mt), mismatch repair-deficient (MMR-d), p53-abnormal (p53-abn), p53-wild-type (p53-wt). These groups might have different pathogenesis and risk factors, and might occur in different phenotypes of patients. However, these data are still lacking. OBJECTIVE: To provide a clinical characterization of the ProMisE groups of EC. METHODS: A systematic review and meta-analysis was performed by searching seven electronic databases from their inception to December 2020, for all studies reporting clinical characteristics of EC patients in each ProMisE group. Pooled means of age and BMI and pooled prevalence of FIGO stage I and adjuvant treatment in each ProMisE group were calculated. RESULTS: Six studies with 1, 879 women were included in the systematic review. Pooled means (with standard error) and prevalence values were: in the MMR-d group, age = 66.5 ± 0.6; BMI = 30.6 ± 1.2; stage I = 72.6%; adjuvant treatment = 47.3%; in the POLE-mt group, age = 58.6 ± 2.7; BMI = 27.2 ± 0.9; stage I = 93.7%; adjuvant treatment = 53.6%; in the p53-wt group, age = 64.2 ± 1.9; BMI = 32.3 ± 1.4; stage I = 80.5%; adjuvant treatment = 45.3%; in the p53-abn group, age = 71.1 ± 0.5; BMI = 29.1 ± 0.5; stage I = 50.8%; adjuvant treatment = 64.4%. CONCLUSION: The ProMisE groups identify different phenotypes of patients. The POLE-mt group included the youngest women, with the lower BMI and the highest prevalence of stage I. The p53-wt group included patients with the highest BMI. The p53-abn group included the oldest women, with the highest prevalence of adjuvant treatment and the lowest prevalence of stage I. The MMR-d group showed intermediate values among the ProMisE groups for all clinical features. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00404-021-06028-4. Springer Berlin Heidelberg 2021-03-23 2021 /pmc/articles/PMC8087601/ /pubmed/33754186 http://dx.doi.org/10.1007/s00404-021-06028-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Raffone, Antonio Travaglino, Antonio Gabrielli, Olimpia Micheli, Mariacarolina Zuccalà, Valeria Bitonti, Giovanna Camastra, Caterina Gargiulo, Valentina Insabato, Luigi Zullo, Fulvio Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title | Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title_full | Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title_fullStr | Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title_full_unstemmed | Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title_short | Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer |
title_sort | clinical features of promise groups identify different phenotypes of patients with endometrial cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087601/ https://www.ncbi.nlm.nih.gov/pubmed/33754186 http://dx.doi.org/10.1007/s00404-021-06028-4 |
work_keys_str_mv | AT raffoneantonio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT travaglinoantonio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT gabrielliolimpia clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT michelimariacarolina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT zuccalavaleria clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT bitontigiovanna clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT camastracaterina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT gargiulovalentina clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT insabatoluigi clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer AT zullofulvio clinicalfeaturesofpromisegroupsidentifydifferentphenotypesofpatientswithendometrialcancer |